Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Masami Bessho"'
Autor:
Tomoya Maeda, Akira Matsuda, Chie Asou, Daisuke Okamura, Ken Tanae, Mika Kohri, Maho Ishikawa, Naoki Takahashi, Kunihiro Tsukasaki, Nobutaka Kawai, Norio Asou, Masami Bessho
Publikováno v:
Leukemia Research Reports, Vol 15, Iss , Pp 100231- (2021)
To determine the impact of peripheral blood (PB) Wilms’ tumour 1 (WT-1) mRNA levels in patients with primary myelodysplastic syndromes (MDS), we analysed the relationships between several clinical variables at the time of diagnosis and the haematol
Externí odkaz:
https://doaj.org/article/f91fb527f32840b09f7f919945b749a1
Autor:
Maho Ishikawa, Akira Matsuda, Daisuke Okamura, Tomoya Maeda, Nobutaka Kawai, Norio Asou, Masami Bessho
Publikováno v:
Hematology Reports, Vol 10, Iss 3 (2018)
Thrombopoietin (TPO) is a critical regulator of hematopoiesis. We previously reported that a severe aplastic anemia (SAA) who received a short-term administration of pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF). A
Externí odkaz:
https://doaj.org/article/4cba731d4cf14a0493be734b2333b100
Autor:
Daisuke Okamura, Akira Matsuda, Maho Ishikawa, Tomoya Maeda, Ken Tanae, Mika Kohri, Naoki Takahashi, Nobutaka Kawai, Norio Asou, Masami Bessho
Publikováno v:
Leukemia Research Reports, Vol 3, Iss 1, Pp 24-27 (2014)
Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine
Externí odkaz:
https://doaj.org/article/9b03b2fea13d445d9eb91ab8e6492c68
Autor:
Ken-ichi Sawada, Makoto Hirokawa, Naohito Fujishima, Masanao Teramura, Masami Bessho, Kazuo Dan, Hisashi Tsurumi, Shinji Nakao, Akio Urabe, Mitsuhiro Omine, Keiya Ozawa, PRCA Collaborative Study Group
Publikováno v:
Haematologica, Vol 92, Iss 8 (2007)
Background and Objectives Cyclosporine A (CsA) has become one of the leading agents for the treatment of pure red cell aplasia (PRCA). However, further studies are necessary to determine the relapse-free survival (RFS) and overall survival (OS) of pa
Externí odkaz:
https://doaj.org/article/37d91ba94d8847b4987053538a6b6e38
Autor:
Chie Asou, Norio Asou, Kunihiro Tsukasaki, Masami Bessho, Nobutaka Kawai, Mika Kohri, Daisuke Okamura, Naoki Takahashi, Akira Matsuda, Tomoya Maeda, Ken Tanae, Maho Ishikawa
Publikováno v:
Leukemia Research Reports, Vol 15, Iss, Pp 100231-(2021)
To determine the impact of peripheral blood (PB) Wilms’ tumour 1 (WT-1) mRNA levels in patients with primary myelodysplastic syndromes (MDS), we analysed the relationships between several clinical variables at the time of diagnosis and the haematol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c63a6adcf301a2ea17e1e325d7d77e92
http://www.sciencedirect.com/science/article/pii/S2213048920300376
http://www.sciencedirect.com/science/article/pii/S2213048920300376
Autor:
Tomoya, Maeda, Akira, Matsuda, Chie, Asou, Daisuke, Okamura, Ken, Tanae, Mika, Kohri, Maho, Ishikawa, Naoki, Takahashi, Kunihiro, Tsukasaki, Nobutaka, Kawai, Norio, Asou, Masami, Bessho
Publikováno v:
Leukemia Research Reports
To determine the impact of peripheral blood (PB) Wilms’ tumour 1 (WT-1) mRNA levels in patients with primary myelodysplastic syndromes (MDS), we analysed the relationships between several clinical variables at the time of diagnosis and the haematol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::688fddbce756d56a14483367e28d8f13
https://pubmed.ncbi.nlm.nih.gov/33354513
https://pubmed.ncbi.nlm.nih.gov/33354513
Autor:
Hideki Kawanishi, Yoshiharu Tsubakihara, Yukio Udagawa, Kotonari Aoki, Masashi Suzuki, Yuzo Watanabe, Yasuo Ohashi, Takashi Akiba, Yoshiki Nishizawa, Masami Bessho, Yasuhiko Tomino, Yukari Uemura, Fumitake Gejyo, Akira Saito, Tadao Akizawa, Hideki Hirakata
Publikováno v:
Therapeutic Apheresis and Dialysis. 20:598-607
Progression of anemia in patients with chronic kidney disease (CKD) is associated with an increased risk of death and hospitalization. It is not sufficiently clear whether treating renal anemia with recombinant human erythropoietin (rHuEPO) has a ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::102962ff4d88df58e4560761e5a56222
https://doi.org/10.1111/1744-9987.12425
https://doi.org/10.1111/1744-9987.12425
Autor:
Hiroko Kobayashi, Fumitaka Suzuki, Nobuyuki Ura, Kazuo Dan, Tetsuya Tsuchida, Yoshihito Uchida, Shigeru Kusumoto, Nobuaki Nakayama, Masashi Mizokami, Hiroshi Kaneko, Kenji Ikeda, Hajime Takikawa, Hiromichi Suzuki, Yasutsuna Sasaki, Kazuhiko Yamamoto, Masamitsu Nakao, Yuichi Nakamura, Satoshi Mochida, Masami Bessho, Hirofumi Fujii, Akio Ido, Sumiko Nagoshi, Toshihide Mimura, Masayoshi Harigai, Hirohito Tsubouchi
Publikováno v:
Journal of Gastroenterology. 51:999-1010
The significance of HBV reactivation during immunosuppressive therapy was evaluated in three nationwide cohorts including patients with previously resolved HBV (prHBV) infection.The clinical features of 1061 patients with acute liver failure (ALF) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7bb2b932e4ebac8465112fefa25db8a
https://doi.org/10.1007/s00535-016-1168-2
https://doi.org/10.1007/s00535-016-1168-2
Autor:
Yukari Uemura, Akira Saito, Yoshiki Nishizawa, Yasuhiko Tomino, Fumitake Gejyo, Masashi Suzuki, Hideki Kawanishi, Yuzo Watanabe, Yukio Udagawa, Yoshiharu Tsubakihara, Tadao Akizawa, Kotonari Aoki, Masami Bessho, Yasuo Ohashi, Takashi Akiba, Hideki Hirakata
Publikováno v:
Therapeutic Apheresis and Dialysis. 18:404-413
Although erythropoiesis-stimulating agents (ESAs) are effective at treating anemia, the association between hemoglobin (Hb) levels and survival is still unclear, especially for the incident Japanese hemodialysis (HD) population. The Japan Erythropoie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd1359894326ddb734cc14d82f820f56
https://doi.org/10.1111/1744-9987.12155
https://doi.org/10.1111/1744-9987.12155
Autor:
Mika Kohri, Norio Asou, Masami Bessho, Naoki Takahashi, Nobutaka Kawai, Ken Tanae, Daisuke Okamura, Tomoya Maeda, Akira Matsuda, Maho Ishikawa
Publikováno v:
Leukemia Research Reports, Vol 3, Iss 1, Pp 24-27 (2014)
Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562806f42426be36168b5ef4f5c98961
https://doi.org/10.1016/j.lrr.2014.03.002
https://doi.org/10.1016/j.lrr.2014.03.002